Ajulemic acid

N/A

Report date: 2023/12/19 18:09:01
NME

Base Information

Drug NameAjulemic acid
Drug Alias NameLenabasumResunabAnabasumHU-239CPL-7075 +[10
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB2 receptor agonists
TargetsCannabinoid CB2 receptor
Therapy Area/IndicationsScleroderma, DiffuseLupus Erythematosus, SystemicCystic Fibrosis +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[26
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicDermatomyositisLupus Vulgaris
Inactive IndicationsScleroderma, DiffuseCystic Fibrosis

Other Information

ATC CodeN/A
Related LinksWikipedia